Clonal evolution and treatment resistance patterns in CRC, particularly to epidermal growth factor receptor (EGFR) blockade, have been well studied, with ctDNA showing a high sensitivity for detecting resistance associated mutations in KRAS, BRAF, and EGFR [20,59,60,61]. The gene discussed is EGFR; the disease is colorectal carcinoma.